Muscle Pain Treatment Market Report 2026

The muscle pain treatment market size has grown strongly in recent years. It will grow from $13.59 billion in 2025 to $14.33 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to rise in physical injuries, increased prevalence of strenuous work conditions, early adoption of otc pain relievers, growth in sports-related muscle strain cases, limited awareness of non-pharmacological therapies.

The muscle pain treatment market size is expected to see strong growth in the next few years. It will grow to $17.42 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to advancement in topical formulations, rising demand for personalized pain management, increasing use of muscle relaxants in clinical care, expansion of physiotherapy centers, growing investment in alternative pain therapies. Major trends in the forecast period include growing demand for topical analgesic products, rising usage of muscle relaxants for acute pain, increasing adoption of physical and massage therapy, expansion of over-the-counter pain relief products, growing focus on combination therapy for chronic muscle pain.

The increasing prevalence of musculoskeletal disorders is expected to drive the growth of the muscle pain treatment market. Musculoskeletal disorders, which affect muscles, bones, and joints, often result in pain, stiffness, and reduced mobility. Factors such as aging populations, sedentary lifestyles, and rising chronic conditions have contributed to the surge in these disorders. Muscle pain treatments aim to relieve symptoms, enhance mobility, prevent complications, and improve overall quality of life. For instance, in January 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, 18.4% of people aged 16 and over reported a long-term musculoskeletal condition in 2023, slightly up from 17.6% in 2022, with higher prevalence among females (20.9%) than males (15.8%). Therefore, the rising incidence of musculoskeletal disorders is propelling the muscle pain treatment market.

Major companies in the muscle pain treatment market are focusing on innovative solutions, such as topical analgesic products, to improve efficacy and convenience for users. Topical analgesics are applied directly to the skin to relieve localized pain, making them useful for muscle aches, arthritis, and minor injuries. For example, in July 2024, Wellness Formulations LLC, a US-based health and wellness company, launched Ralli Rapid Pain Relief, which combines menthol’s pain-relieving properties with advanced skin penetration enhancers. Available in gel, spray, and roll-on formats, it provides fast, effective pain relief without greasy residue, targeting muscles, joints, and strains directly.

In November 2025, Physician Partners of America (PPOA), a US-based interventional pain management provider, acquired Crespo Injury Care Center for an undisclosed amount. This acquisition allows PPOA to expand its presence in the Tampa Bay region and enhance access to high-quality musculoskeletal and interventional pain care. Crespo Injury Care Center specializes in injury-focused pain management, sports medicine, orthopedic care, and rehabilitation services, strengthening PPOA’s service portfolio and regional reach.

Major companies operating in the muscle pain treatment market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Haleon Plc, Select Medical Holdings Corporation, Purdue Pharma, Endo Pharmaceuticals Inc., Concentra Inc., Athletico Physical Therapy, ATI Physical Therapy Inc., Physiotherapy Associates Inc, NovaCare Rehabilitation Inc, CORA Health Services Inc., Select Physical Therapy Holdings Inc., ProActive Physical Therapy.

North America was the largest region in the muscle pain treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle pain treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the muscle pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of raw materials, pharmaceutical ingredients, and medical devices used in the muscle pain treatment market, leading to higher production and distribution expenses for analgesics, topical products, and therapy equipment. Regions dependent on imported NSAIDs and muscle relaxants face delays and higher retail prices. However, tariffs have pushed manufacturers toward local sourcing and domestic production expansion, creating potential long-term cost stabilization and improved supply chain resilience.

The muscle pain treatment market research report is one of a series of new reports that provides muscle pain treatment market statistics, including muscle pain treatment industry global market size, regional shares, competitors with a muscle pain treatment market share, detailed muscle pain treatment market segments, market trends and opportunities, and any further data you may need to thrive in the muscle pain treatment industry. This muscle pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Muscle pain treatment refers to the management and relief of discomfort and inflammation in the muscles. It typically involves rest, heat or cold therapy, over-the-counter pain relievers, and, in severe cases, physical therapy or prescription medications. The goal of treatment is to reduce pain, promote healing, and restore normal muscle function.

The main pharmacological treatments for muscle pain include analgesics, muscle relaxants, topical analgesics, and others. Analgesics are medications that relieve pain without causing loss of consciousness. Non-pharmacological treatments include physical therapy, massage, acupuncture, heat and cold therapy, exercise, stretching, and more. These treatments address various types of muscle pain, including acute and chronic pain caused by overuse, strain, injury, trauma, inflammatory conditions, neurological disorders, infections, and others. They are applied in settings such as hospitals, clinics, and other healthcare facilities.

The muscle pain treatment market consists of revenues earned by entities by providing services such as chiropractic care, hydrotherapy, occupational therapy, transcutaneous electrical nerve stimulation (TENS), cognitive-behavioral therapy (CBT), and myofascial release therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle pain treatment market also includes sales of acetaminophen, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.